ArticleInternational ophthalmology2026
Assesment of oxidative stress and antioxidant status in pseudoexfoliation syndrome with ocular and systemic comorbidities.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate oxidative stress (OS) markers and thiol-disulfide homeostasis (TDH) in patients with pseudoexfoliation (PEX) syndrome and to investigate their associations with ocular and systemic comorbidities.
methodsThis case-control study included 89 participants, comprising 45 patients with PEX and 44 age- and sex-matched controls. Serum oxidative stress parameters, including total thiol (TT), native thiol (NT), disulfide, thiol-disulfide ratios, total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI), were measured and compared between groups. The diagnostic utility of OS biomarkers was assessed through receiver operating characteristic curve (ROC) analysis. Additionally, the interrelationships among these biomarkers and their associations with ocular and systemic comorbid conditions observed in PEX were examined.
resultsTT and NT levels were significantly higher in PEX patients whereas disulfide, disulfide/TT, disulfide /NT and TAS were significantly lower. PEX patients revealed a 1.18‑fold increased risk of glaucoma with elevated disulfide and a 1.61‑times increased risk of hypertension with elevated disulfide levels. ROC evaluation demonstrated a high level of diagnostic capability: TT (AUC = 0.808, cut-off 416 µmol/L, sensitivity 69%, specificity 86%), NT (AUC = 0.827, cut-off 377 µmol/L, sensitivity 67%, specificity 91%), and disulfide (AUC = 0.681, cut-off 23.5 µmol/L, sensitivity 80%, specificity 52%).
conclusionAlthough our study shows that thiol-disulfide homeostasis appears to be significantly associated with glaucoma and hypertension in PEX patients, this relationship is not equally distributed across all comorbid conditions examined, and oxidative imbalance plays a more selective role in the disease burden associated with PEX.
Indexed as
Identifiers
42371156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.